Spots Global Cancer Trial Database for hydroxychloroquine
Every month we try and update this database with for hydroxychloroquine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hydroxychloroquine in Untreated B-CLL Patients | NCT00771056 | B-Cell Chronic ... | Hydroxychloroqu... | 18 Years - | Northwell Health | |
| Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance | NCT02421575 | Prostate Carcin... | Hydroxychloroqu... Laboratory Biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance | NCT02421575 | Prostate Carcin... | Hydroxychloroqu... Laboratory Biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) | NCT01602588 | Glioblastoma | Hydroxychloroqu... Radiotherapy | 70 Years - 100 Years | University College, London | |
| Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | NCT03037437 | Hepatocellular ... | Sorafenib (SOR) Hydroxychloroqu... | 18 Years - 100 Years | The University of Texas Health Science Center at San Antonio | |
| Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00486603 | Brain and Centr... | hydroxychloroqu... temozolomide pharmacological... Radiation | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | NCT01510119 | Metastatic Clea... | Hydroxychloroqu... RAD001 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | NCT01144169 | Renal Cell Carc... | Hydroxychloroqu... | 19 Years - | University of Pittsburgh | |
| Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00568880 | Multiple Myelom... | bortezomib hydroxychloroqu... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | NCT00728845 | Lung Cancer | bevacizumab carboplatin hydroxychloroqu... paclitaxel | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | NCT02631252 | Leukemia, Acute... | Hydroxychloroqu... Mitoxantrone Etoposide | 18 Years - 80 Years | University of Pittsburgh | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas | NCT04145297 | Gastrointestina... | Ulixertinib Hydroxychloroqu... | 18 Years - | University of Utah | |
| Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | NCT04787991 | Metastatic Panc... | Nivolumab (Coho... Ipilimumab (Coh... Hydroxychloroqu... Nab-paclitaxel ... Gemcitabine (ge... NG350A (Cohort ... | 18 Years - | Cancer Insight, LLC | |
| Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study. | NCT04760080 | Dermatology and... | pre-treatment d... during study tr... | 18 Years - | Hospices Civils de Lyon | |
| Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer | NCT01273805 | Pancreatic Canc... | Hydroxychloroqu... | 18 Years - | Dana-Farber Cancer Institute | |
| Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer | NCT01494155 | Pancreatic Canc... | Capecitabine Hydroxychloroqu... Proton or Photo... | 18 Years - | Massachusetts General Hospital | |
| Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients | NCT01292408 | Breast Cancer | Hydrochloroquin... | - | Radboud University Medical Center | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma | NCT03754179 | Melanoma | Dabrafenib Trametinib Hydroxychloroqu... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer | NCT01494155 | Pancreatic Canc... | Capecitabine Hydroxychloroqu... Proton or Photo... | 18 Years - | Massachusetts General Hospital | |
| CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | NCT03032406 | Breast Cancer S... | Hydroxychloroqu... Everolimus | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | NCT02765594 | Primary IgA Nep... | Hydroxychloroqu... Valsartan | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | NCT01227135 | Leukemia | hydroxychloroqu... imatinib mesyla... cytogenetic ana... polymerase chai... laboratory biom... pharmacological... | 18 Years - | University of Glasgow | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | NCT03037437 | Hepatocellular ... | Sorafenib (SOR) Hydroxychloroqu... | 18 Years - 100 Years | The University of Texas Health Science Center at San Antonio | |
| Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00962845 | Melanoma (Skin) | hydroxychloroqu... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | NCT01396200 | Myeloma | Hydroxychloroqu... Rapamycin | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) | NCT01026844 | Non-small Cell ... | erlotinib hydroxychloroqu... | 18 Years - | Massachusetts General Hospital | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer | NCT03825289 | Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Hydroxychloroqu... Trametinib | 18 Years - | University of Utah | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | NCT05843188 | Metastatic Colo... | Hydroxychloroqu... Irinotecan Leucovorin Fluorouracil Bevacizumab | 18 Years - | University Health Network, Toronto | |
| Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00714181 | Unspecified Adu... | hydroxychloroqu... temozolomide TdT-mediated dU... western blottin... electron micros... high performanc... immunoenzyme te... immunohistochem... laboratory biom... mass spectromet... pharmacological... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | NCT04201457 | Low Grade Gliom... High Grade Glio... Low Grade Gliom... | Dabrafenib Trametinib Hydroxychloroqu... | 1 Year - 30 Years | Pediatric Brain Tumor Consortium | |
| Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | NCT02316340 | Colorectal Canc... | Vorinostat Hydroxychloroqu... Regorafenib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | NCT01144169 | Renal Cell Carc... | Hydroxychloroqu... | 19 Years - | University of Pittsburgh | |
| Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | NCT00726596 | Prostate Cancer | hydroxychloroqu... | 18 Years - | Rutgers, The State University of New Jersey | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | NCT00977470 | Non-small Cell ... | Erlotinib Hydroxychloroqu... | 18 Years - | Massachusetts General Hospital | |
| A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 | NCT04379492 | COVID-19 COVID19 Sars-CoV2 SARS-Cov-2 | Hydroxychloroqu... Placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | NCT01128296 | Pancreatic Canc... | Hydroxychloroqu... Gemcitabine | 19 Years - | University of Pittsburgh | |
| HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors | NCT02232243 | Solid Tumor | Hydroxychloroqu... Hydroxychloroqu... | 18 Years - | University of Kentucky | |
| Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00714181 | Unspecified Adu... | hydroxychloroqu... temozolomide TdT-mediated dU... western blottin... electron micros... high performanc... immunoenzyme te... immunohistochem... laboratory biom... mass spectromet... pharmacological... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | NCT05733000 | Advanced Biliar... Advanced Colore... Advanced Gastro... Advanced Lung A... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Urothe... Clinical Stage ... Clinical Stage ... Metastatic Bili... Metastatic Colo... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Metastatic Panc... Metastatic Urot... Refractory Bili... Refractory Colo... Refractory Gast... Refractory Lung... Refractory Ovar... Refractory Panc... Refractory Urot... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre... | Biospecimen Col... Computed Tomogr... Devimistat Fluorouracil Gemcitabine Hyd... Hydroxychloroqu... Magnetic Resona... | 18 Years - | Northwestern University | |
| Evaluation of Hydroxychloroquine to Prevent CIPN | NCT05689359 | Breast Cancer Gynecologic Can... Early-stage Bre... Peripheral Neur... Chemotherapy-in... | Hydroxychloroqu... | 21 Years - | University of Arizona | |
| Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer | NCT03825289 | Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Hydroxychloroqu... Trametinib | 18 Years - | University of Utah | |
| Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | NCT01266057 | Advanced Cancer... | Hydroxychloroqu... Sirolimus Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases | NCT01417403 | Bone Metastases Unspecified Adu... | hydroxychloroqu... radiation thera... | 18 Years - | Virginia Commonwealth University | |
| Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma | NCT04163107 | Multiple Myelom... | Hydroxychloroqu... Carfilzomib Inj... Dexamethasone | 18 Years - | Norwegian University of Science and Technology | |
| Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors | NCT03015324 | Solid Tumor | Hydroxychloroqu... | 18 Years - | University of Kentucky | |
| Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | NCT00786682 | Prostate Cancer | docetaxel hydroxychloroqu... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | NCT04464759 | Melanoma | Nivolumab Hydroxychloroqu... Ipilimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy | NCT02414776 | Estrogen Recept... | hydroxychloroqu... | 18 Years - | Western Regional Medical Center | |
| Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis | NCT03449758 | Rheumatoid Arth... | SARILUMAB Azathioprine Chloroquine Hydroxychloroqu... Leflunomide Methotrexate Sulfasalazine | 18 Years - | Sanofi | |
| FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | NCT01206530 | Rectal Cancer Colon Cancer Metastasis Adenocarcinoma | Hydroxychloroqu... Oxaliplatin Leucovorin 5-fluorouracil 5-fluorouracil Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | NCT01828476 | Prostate Cancer | Abiraterone ABT-263 Hydroxychloroqu... | 18 Years - | Rutgers, The State University of New Jersey | |
| ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer | NCT04523857 | Breast Cancer | Abemaciclib Hydroxychloroqu... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | NCT01144169 | Renal Cell Carc... | Hydroxychloroqu... | 19 Years - | University of Pittsburgh | |
| STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) | NCT02722369 | Small Cell Lung... | Gemcitabine Carboplatin Etoposide Hydroxychloroqu... | 18 Years - | University College, London | |
| Hydroxychloroquine and Gefitinib to Treat Lung Cancer | NCT00809237 | Non-small Cell ... | Gefitinib, Hydr... | 21 Years - | National University Hospital, Singapore | |
| Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer | NCT00765765 | Breast Cancer | hydroxychloroqu... ixabepilone | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | NCT04524702 | Advanced Pancre... Metastatic Panc... Stage IV Pancre... | Gemcitabine Hydroxychloroqu... Nab-paclitaxel Paricalcitol | 18 Years - | Emory University | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine | NCT01978184 | Pancreatic Canc... | gemcitabine abraxane hydroxychloroqu... | 18 Years - | University of Pittsburgh | |
| Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | NCT01128296 | Pancreatic Canc... | Hydroxychloroqu... Gemcitabine | 19 Years - | University of Pittsburgh | |
| Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients | NCT04341207 | Cancer & COVID ... | Hydroxychloroqu... Azithromycin | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | NCT01227135 | Leukemia | hydroxychloroqu... imatinib mesyla... cytogenetic ana... polymerase chai... laboratory biom... pharmacological... | 18 Years - | University of Glasgow | |
| Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance | NCT02421575 | Prostate Carcin... | Hydroxychloroqu... Laboratory Biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer | NCT05647330 | Hydroxychloroqu... Gemcitabine Lung Neoplasms | Hydroxychloroqu... | 18 Years - 70 Years | Henan Cancer Hospital | |
| Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00962845 | Melanoma (Skin) | hydroxychloroqu... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00486603 | Brain and Centr... | hydroxychloroqu... temozolomide pharmacological... Radiation | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases | NCT01417403 | Bone Metastases Unspecified Adu... | hydroxychloroqu... radiation thera... | 18 Years - | Virginia Commonwealth University | |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737 | Malignant Solid... | Hydroxychloroqu... Vorinostat | 16 Years - | The University of Texas Health Science Center at San Antonio | |
| Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | NCT01266057 | Advanced Cancer... | Hydroxychloroqu... Sirolimus Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer | NCT04669197 | Untreated Resec... Borderline Rese... Locally Advance... | Paclitaxel prot... Gemcitabine Cisplatin Hydroxychloroqu... | 18 Years - | HonorHealth Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
